Fannie Mae, Freddie Mac shares tumble after conservatorship comments
In a recent transaction, RTW Investments, LP, a significant stakeholder in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO), acquired 49,900 shares of the company’s common stock. The shares were purchased at a price of $2.99 each, totaling approximately $149,201. The timing appears strategic, as InvestingPro data shows the stock has gained over 15% in the past week, while maintaining impressive gross profit margins above 92%. This acquisition increases RTW Investments’ holdings to 8,306,063 shares. The transaction reflects the continued interest and investment by RTW Investments, led by Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer. The shares are held by funds affiliated with RTW Investments, and the reporting persons have disclaimed beneficial ownership except to the extent of their pecuniary interest. According to InvestingPro analysis, OBIO currently trades below its Fair Value, with analyst price targets ranging from $12 to $20. Subscribers can access 8 additional key insights about OBIO’s financial health and growth prospects.
In other recent news, Orchestra BioMed has made significant strides with its Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) after the FDA approved a pivotal clinical trial. This trial will compare Virtue SAB with Boston Scientific (NYSE:BSX)’s AGENT paclitaxel-coated balloon, involving 740 patients across up to 75 U.S. centers. Meanwhile, H.C. Wainwright has maintained a Buy rating for Orchestra BioMed, setting a price target of $12, following the company’s report of a $61 million net loss for 2024 and revenue of $2.6 million. The firm also noted the progress in the BACKBEAT pivotal study of the atrioventricular interval modulation (AVIM) therapy. Additionally, the FDA granted Breakthrough Device Designation to the AVIM therapy, which is anticipated to expedite its development and review process. BTIG analyst Marie Thibault also confirmed a Buy rating with a $12 target, despite Orchestra BioMed’s fourth-quarter revenue falling short of expectations. The company’s financial position remains strong with $66.8 million in cash, equivalents, and marketable securities at the end of 2024. The upcoming resolution of partnership restructuring negotiations with Terumo Corporation is highlighted as a potential influence on the company’s future developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.